Abstract: Provided are compounds of the Formula (I), or their pharmaceutically acceptable salts, wherein X1, X2, X3, A1, A2, R1-R7, R8a, R8b, R9a, R9b, R10 and R11 are as herein described. can trap IL-1? and are expected to have utility as therapeutic agents, for example, for treating cardiovascular disease and inflammatory disorders. The disclosure also provides pharmaceutical compositions which comprise the compounds disclosed herein or pharmaceutically acceptable salts thereof. The disclosure also relates to methods for use of the compounds or their pharmaceutically acceptable salts in the therapy and prophylaxis of cardiovascular disease and inflammatory disorders and for preparing pharmaceuticals for this purpose.

Abstract: There is described herein, multimers comprising a plurality of compounds covalently linked together, the compounds independently being of formula (I).

Abstract: There is described herein, multimers comprising a plurality of compounds covalently linked together, the compounds independently being of formula (I).

Abstract: There is described herein antagonists of ?4?7 integrin, and more particularly cyclic peptide antagonists, such as compounds of formula (I).

Abstract: There is described herein, multimers comprising plurality of compounds covalently linked together, the compounds independently being of formula (I).

Abstract: There is described herein antagonists of ?4?7 integrin, and more particularly to cyclic peptide antagonists. Accordingly, there is described herein a compound of formula (I) wherein R1, R2, R3, R4, R5, R6, R7 and R8 are various substituents; stereocentres 1*, 2* and 3* are each independently selected from R and S; n is 1, 2, 3, or 4 and where n is 2-4, Z is an amino terminus of an amino acid; —C?O— adjacent L is the carboxy terminus of an amino acid; and L along with Z and —C?O— is a peptide.

Abstract: There is described herein, multimers comprising a plurality of compounds covalently linked together, the compounds independently being of formula (I).

Abstract: There is described herein antagonists of ?4?7 integrin, and more particularly to cyclic peptide antagonists. Accordingly, there is described herein a compound of formula (I) wherein R1, R2, R3, R4, R5, R6, R7 and R8 are various substituents; stereocentres 1*, 2* and 3* are each independently selected from R and S; n is 1, 2, 3, or 4 and where n is 2-4, Z is an amino terminus of an amino acid; —C?O— adjacent L is the carboxy terminus of an amino acid; and L along with Z and —C?O— is a peptide.

Abstract: There is described herein use of a compound of formula (I) below to make cyclic peptides.

Abstract: There is described herein use of a compound of formula (I) below to make cyclic peptides.

Abstract: There is described herein use of a compound of formula (I) below to make cyclic peptides.

Abstract: There is described herein, multimers comprising a plurality of compounds covalently linked together, the compounds independently being of formula (I).

Abstract: There is described herein antagonists of ?4?7 integrin, and more particularly to cyclic peptide antagonists. Accordingly, there is described herein a compound of formula (I) wherein R1, R2, R3, R4, R5, R6, R7 and R8 are various substituents; stereocentres 1*, 2* and 3* are each independently selected from R and S; n is 1, 2, 3, or 4 and where n is 2-4, Z is an amino terminus of an amino acid; —C?O— adjacent L is the carboxy terminus of an amino acid; and L along with Z and —C?O— is a peptide.

Abstract: There is described herein antagonists of ?4?7 integrin, and more particularly cyclic peptide antagonists, such as compounds of formula (I).

Abstract: There is described herein use of a compound of formula (I) below to make cyclic peptides.

Abstract: The present invention relates to cyclic amino acid molecules and methods of preparing the same, and in particular the macrocyclization of amino acids or linear peptides bound to a solid support.